News

Filter

Current filters:

BayerEli Lilly

Global insulin market expanded to $20.8 billion in 2012

17-12-2013

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular…

Asia-PacificBayerChinaDiabetesEli LillyGlobalMarkets & MarketingNovo NordiskSanofi

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Study finds "Big Pharma" fails at self-policing ED drug advertising

18-02-2013

The pharmaceutical industry's efforts to self-regulate its direct-to-consumer (DTC) advertising are "an…

BayerCialisEli LillyLevitraMarkets & MarketingMen's HealthPfizerPharmaceuticalRegulationViagra

Nexavar use in Chinese patients nearly doubled in 2012

19-12-2012

Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

More news from ASCO meeting

05-06-2012

More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

Chiesi, Eli Lilly and Bayer named for breaches of the ABPI Code of Practice

31-05-2011

The UK subsidiaries of Italy’s Chiesi, US drug major Eli Lilly (NYSE: LLY) and Germany’s Bayer…

BayerChiesi FarmaceuticiEli LillyEuropeLevitraNeurologicalPharmaceuticalRegulationReproductiveYasmin

COMPANY SPOTLIGHT

Menarini

Back to top